Establishment of molecular targeting therapy against ovarian cancer using human monoclonal antibody
Establishment of molecular targeting therapy against ovarian cancer using human monoclonal antibody
批准号:
17591759
负责人:
SUZUKI Nao
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
目的:近年来,利用单克隆抗体进行抗体治疗已成为治疗肿瘤的新途径。本研究利用KM小鼠建立识别CA125相关表位的人单克隆抗体,并评估其与卵巢癌细胞的反应性。方法:采用人卵巢透明细胞腺癌细胞系(RMG-I)免疫KM小鼠,采用ELISA筛选标准方法获得杂交瘤上清。接下来,用两种抗体(MA602-1和MA602-6)筛选杂杂瘤,并对ca125样抗原进行夹心免疫测定,然后用极限稀释获得人单克隆抗体。评估该抗体(HMOCC-2)与卵巢癌的免疫组化反应性,并通过Western blotting分析其特异性。利用多种抗体鉴定HMOCC-2靶向的表位。最后,通过对异种rmg - 1肿瘤移植的SCID小鼠腹腔注射HMOCC-2来评估其抗肿瘤作用。结果:60%(63/105)的卵巢癌标本HMOCC-2阳性。RMG-I膜组分的Western blotting在120kda至250kda范围内显示出多条条带。HMOCC-2识别了几种抗体所识别的ca125样抗原。HMOCC-2对卵巢癌异种移植物也有显著的抗肿瘤活性(p<0.01)。结论:HMOCC-2通过类似于CA125的靶表位特异性作用于卵巢癌细胞,并表现出抗卵巢肿瘤的活性。这些发现表明,它可能具有应用于临床分子靶向治疗的潜力。
英文摘要
Objective : In recent years, antibody therapy employing monoclonal antibodies has become a new approach for treating cancer. This study was performed to establish a human monoclonal antibody recognizing an epitope related to CA125 using KM mice and to assess its reactivity with ovarian cancer cells.Methods : A human ovarian clear cell adenocarcinoma cell line (RMG-I) was used to immunize KM mice, and hybridoma supernatant was obtained by a standard method employing ELISA screening. Next, selection of hybridomas was performed with two antibodies (MA602-1 and MA602-6) and a sandwich immunoassay for CA125-like antigen, and then the limiting dilution was used to obtain a human monoclonal antibody.Immunohistochemical reactivity of this antibody (HMOCC-2) with ovarian cancer was assessed, while its specificity was analyzed by Western blotting. Various antibodies were used to identify the epitope targeted by HMOCC-2. Finally, the antitumor effect of HMOCC-2 was assessed by intraperitoneal administration to SCID mice with heterografts of RMG-I tumors.Results : HMOCC-2 showed a positive reaction with 60% (63/105) of ovarian cancer specimens. Western blotting of the membrane fraction of RMG-I revealed several bands at 120 kDa to 250 kDa. HMOCC-2 recognized the CA125-like antigens identified by several antibodies. HMOCC-2 also exhibited significant antitumor activity (p<0.01) against ovarian cancer heterografts.Conclusion : HMOCC-2 reacts specifically with ovarian cancer cells via a target epitope analogous to that of CA125, and also exhibits activity against ovarian tumors. These findings suggest that it may have the potential to be employed clinically for molecular-targeting therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovative Technological Development of Fertility Preservation Treatment Oriented to Improve Cancer Survivorship
-
批准号:20H03830
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.4万
-
财政年份:2020
-
负责人:SUZUKI Nao
-
依托单位:
The research that aims at the establishment of an efficient ovarian tissue cryopreservation and transplantation method - For the young female cancer patients
-
批准号:23592421
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2011
-
负责人:SUZUKI Nao
-
依托单位:
Basic research on the auto-transplantation of cryopresedved ovarian tissue - Aiming at the quality of life improvement of the young woman cancer patient.
-
批准号:20591933
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2008
-
负责人:SUZUKI Nao
-
依托单位:
Analysis of molecular signal transduction pathway between M-CSF and c-fms involved in uterine cervical cancer
-
批准号:13671744
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2001
-
负责人:SUZUKI Nao
-
依托单位:
海外基金